Background Acute lymphoblastic leukemia (ALL) is the most common pediatric
hematological malignancy, with ETV6:: RUNX1 being the most prevalent translocation …

Cure rates in pediatric acute lymphoblastic leukemia (ALL) currently approach 90% in the
developed world. Treatment involves 6-8 mo of intensive multi-drug chemotherapy followed …

Introduction Currently, there are no guidelines for the management of B-cell lineage acute
lymphoblastic leukemia (B-ALL) from an Indian perspective. The diagnostic workup …

Overexpression of cytokine receptor-like factor 2 (CRLF2) resulting from its genomic
rearrangement is the most frequent genetic alteration found in Philadelphia chromosome …

Methotrexate-induced neurotoxicity is a well-defined side-effect of high-dose and intrathecal
methotrexate with characteristic clinico-radiological findings and transient nature. Our …

Objective During the 2-year maintenance treatment phase (MT) of acute lymphoblastic
leukemia (ALL), personalized patient-specified titration of oral antimetabolite drug doses is …

Objectives Restriction of raw fruits and vegetables (neutropenic diet) is advised for patients
receiving treatment for acute leukaemia in low-income and middle-income countries (LMICs) …

Philadelphia chromosome positive (Ph+) acute lymphoblastic lymphoma (ALL) is an
uncommon subtype of ALL in children, seen in 2–5% cases. Diagnostic evaluation includes …

Introduction Pediatric T-cell acute lymphoblastic leukemia (T-ALL) poses significant
challenges due to its aggressive nature and resistance to standard treatments. Long non …

Despite major biomedical advancements in various realms of oncology, the benefits of these
developments are not equitably distributed, particularly in underresourced settings. Although …